Literature DB >> 15550029

Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor.

D Maret1, M B Boffa, D F Brien, M E Nesheim, M L Koschinsky.   

Abstract

Regulation of mRNA stability has emerged as a major control point in eukaryotic gene expression. The abundance of a particular mRNA can be rapidly regulated in response to a stimulus by altering the stability of existing translatable transcripts rather than by altering the rate of transcription initiation. Alternative polyadenylation of transcripts during mRNA processing can be important in determining transcript abundance if the different forms of mRNA possess different stabilities or translatability. The mRNA transcript encoding thrombin activable fibrinolysis inhibitor (TAFI) is an attractive candidate for regulation of mRNA stability because of the relatively long length of its 3'-untranslated region and because the transcript can be polyadenylated at three different sites. As well, we have previously reported that treatment of HepG2 cells with interleukins (IL) - 1beta and - 6 destabilizes the endogenous TAFI mRNA expressed in this cell line. In the current study, we report that the TAFI 3'-untranslated region contains cis-acting instability element(s) and that these elements in fact determine the intrinsic stability of the TAFI transcript. Moreover, we found that the three different polyadenylated mRNA forms have different intrinsic stabilities, with the mRNA half-life increasing from the longest to the shortest transcript. Interestingly, treatment with IL-1beta plus IL-6 not only resulted in a 2-fold decrease in stability of the transcript produced using the 3'-most polyadenylation site but also resulted in profound shifts in the relative abundances of the respective polyadenylated forms through changes in the frequency of utilization of the three polyadenylation sites. As such, in the presence of IL-1beta and IL-6, the longest transcript is over a thousand times more abundant than the two shorter transcripts whereas in the absence of the stimulus it comprises only 1% of the total TAFI transcripts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550029     DOI: 10.1111/j.1538-7836.2004.00971.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.

Authors:  Jaya Rajaiya; Jamee C Nixon; Neil Ayers; Zana P Desgranges; Ananda L Roy; Carol F Webb
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

2.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

3.  Preferential regulation of stably expressed genes in the human genome suggests a widespread expression buffering role of microRNAs.

Authors:  Zhen Yang; Dong Dong; Zhaolei Zhang; M James C Crabbe; Li Wang; Yang Zhong
Journal:  BMC Genomics       Date:  2012-12-13       Impact factor: 3.969

4.  Riboswitch-dependent gene regulation and its evolution in the plant kingdom.

Authors:  Samuel Bocobza; Avital Adato; Tali Mandel; Michal Shapira; Evgeny Nudler; Asaph Aharoni
Journal:  Genes Dev       Date:  2007-11-15       Impact factor: 11.361

5.  MicroRNA regulation and the variability of human cortical gene expression.

Authors:  Rui Zhang; Bing Su
Journal:  Nucleic Acids Res       Date:  2008-07-10       Impact factor: 16.971

6.  Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.

Authors:  You Li; Zhiliang Zeng; Jianghao Zhao; Guoda Ma; Lili Cui; Hua Tao; Zhijun Lin; Yanyan Chen; Bin Zhao; Yusen Chen; Keshen Li
Journal:  Lipids Health Dis       Date:  2014-05-13       Impact factor: 3.876

7.  A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.

Authors:  Tara M Stanne; Maja Olsson; Erik Lorentzen; Annie Pedersen; Anders Gummesson; Ann Gils; Katarina Jood; Gunnar Engström; Olle Melander; Paul J Declerck; Christina Jern
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.